Fibrinolysis for patients with intermediate-risk pulmonary embolism.

Meyer, G.; Vicaut, E.; Danays, T.; Agnelli, G.; Becattini, C.; Beyer-Westendorf, J.; Bluhmki, E.; Bouvaist, H.; Brenner, B.; Couturaud, F.; Dellas, C.; Empen, K.; França, A.; Galiè, N.; Geibel, A.; Goldhaber, S.; Jiménez, D.; Kozak, M.; Kupatt, C.; Kucher, N.; Lang, I.; Lankeit, M.; Meneveau, N.; Pacouret, G.; Palazzini, M.; Petriş, A.; Pruszczyk, P.; Rugolotto, M.; Salvi, A.; Schellong, S.; Sebbane, M.; Sobkowicz, B.; Stefanović, B.; Thiele, H.; Torbicki, A.; Verschuren, F.; Konstantinides, S.

doi:10.1056/NEJMoa1302097

Public

Fibrinolysis for patients with intermediate-risk pulmonary embolism.

Shared by NobleBlocks on Apr 9, 2014 • 12:00 AM UTC

Authors:

G. Meyer

E. Vicaut

T. Danays

Abstract

BACKGROUND The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. METHODS In a randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in normotensive patients with intermediate-risk pulmonary embolism. Eligibl...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!